AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

- AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritis

- New data for risankizumab and upadacitinib provide further evidence supporting efficacy and safety across diverse patient populations

- Data evaluating investigational compounds lutikizumab and zumilokibart will also be presented, highlighting AbbVie's ongoing research in additional mechanisms of action

NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapies, SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib).

"At EADV, we are excited to share new data that further strengthen the growing evidence base across our dermatology portfolio, including SKYRIZI, RINVOQ and investigational therapies," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. "These findings underscore our ongoing research in advancing scientific understanding and delivering innovative treatment options that have the potential to meaningfully improve outcomes for patients across a broad spectrum of immune-mediated skin diseases."

Key data to be presented across the following therapeutic areas include:

- Alopecia Areata (AA): 52-week data on the long-term efficacy and safety of upadacitinib from the Phase 3 UP-AA trials, alongside new analyses evaluating improvements in patients' quality of life following upadacitinib treatment.

- Atopic Dermatitis (AD): 

- Late-breaking presentation of the primary 16-week results from the Phase 2 APEX Part B dose-regimen-finding study evaluating the efficacy and safety of zumilokibart in moderate to severe AD. Results from the Phase 2 APEX Part A study evaluating maintenance and improvement of response with zumilokibart through 52 weeks, as well as efficacy in patients with AD and evidence of type 2 inflammatory comorbidities.

- Data from both real-world registries and clinical trial settings evaluating the efficacy of upadacitinib in specific patient populations, including those with moderate disease, hand eczema or an itch-dominant phenotype.

- Hidradenitis Suppurativa (HS): 

- Late-breaking presentation showing how lutikizumab targets neutrophilic inflammation and fibroblast activation in HS.

- Results from a Phase 2 study evaluating the impact of lutikizumab on symptom burden, disease burden and quality of life in patients with moderate-to-severe HS. An additional analysis of this Phase 2 study will assess the impact on disease severity according to the International Hidradenitis Suppurativa Severity Score System (IHS4) with lutikizumab.

- Non-segmental Vitiligo (NSV): Analyses from two Phase 3 trials (Viti-Up 1 and 2) of upadacitinib in adults and adolescents with NSV, evaluating patient-reported outcomes, disease stabilization and repigmentation, week 48 efficacy and safety data as well as week 76 continued repigmentation response. Findings from a phototherapy substudy evaluating the efficacy and safety of RINVOQ in combination with narrow band ultraviolet (NB-UVB) phototherapy and RINVOQ monotherapy after 28 weeks.

- Psoriasis (PsO): Efficacy and safety results from several real-world and clinical studies of risankizumab in patients with moderate to severe PsO, including adults with high-impact area involvement and Week 52 data in pediatric patients.

- Other key data include results from a head-to-head trial evaluating risankizumab vs. deucravacitinib in moderate psoriasis patients, and a retrospective, real-world study evaluating the association of risankizumab and other targeted immunomodulators on risk of developing psoriatic arthritis in adults with PsO.

- Other key data include results from a head-to-head trial evaluating risankizumab vs. deucravacitinib in moderate psoriasis patients, and a retrospective, real-world study evaluating the association of risankizumab and other targeted immunomodulators on risk of developing psoriatic arthritis in adults with PsO.

- Psoriatic Arthritis (PsA): A post-hoc analysis of the Phase 3 KEEPsAKE-1 trial will evaluate radiographic progression in patients with active PsA treated with risankizumab according to their risk of joint erosive disease.

The 2026 EADV Congress program is available here, including the late-breaking sessions. Select abstracts and oral presentations from AbbVie include:

About RINVOQ® (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,2 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1 Indications

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis

RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis

RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata

RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo

RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications

RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use

RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;

- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);

- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)

Use in patients 65 years of age and older

Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products

Use in combination with other potent immunosuppressants is not recommended.

Serious infections

Serious and sometimes fatal infections have been reported in patients receiving RINVOQ.